Thiocolchiside and acelofenac drug side effect and drug interactions
Reading File
Finding Sources
Finding Sources
Searching the Web
thiocolchicoside aceclofenac side effects drug interactions 2024
Finding Sources
Reading Web Page
https://www.apollohospitals.com/medicines/thiocolchicoside
Finding Sources
Reading File
Reading Web Page
https://www.ema.europa.eu/en/news/european-medicines-agency-…
Searching PubMed
aceclofenac NSAID adverse effects
I now have comprehensive information to provide a detailed, well-structured answer. Here it is:
Thiocolchicoside & Aceclofenac - Side Effects and Drug Interactions
These two drugs are commonly prescribed together as a fixed-dose combination for musculoskeletal pain and muscle spasms. Below is a detailed breakdown of each drug, followed by combination-specific considerations.
1. THIOCOLCHICOSIDE
Class: Centrally acting muscle relaxant (GABA-A receptor modulator / glycine receptor agonist)
ATC Code: M03BX05
Usual Dose: 8 mg orally twice daily (max 7 days oral/injectable course per EMA guidelines)
Side Effects
Common (>1/100):
- Drowsiness / sedation
- Dizziness
- Nausea and vomiting
- Dry mouth
- Fatigue
Serious / Rare:
- Allergic reactions - rash, urticaria, angioedema, anaphylaxis
- Severe dizziness or syncope
- Hepatotoxicity - jaundice, dark urine, elevated liver enzymes
- Seizures (reported with high doses)
- Diarrhea
Genotoxicity Warning (EMA Regulatory Alert):
The EMA's CHMP reviewed evidence showing that the metabolite M2 (3-demethylthiocolchicine / SL59.0955) causes aneuploidy (abnormal chromosome number) in dividing cells at exposure levels not much greater than recommended oral doses. This makes thiocolchicoside:
- A teratogen / embryotoxin risk
- A risk for spontaneous abortion
- A cause of impaired male fertility
- Theoretically associated with increased cancer risk with prolonged use (though not mutagenic or clastogenic)
The EMA therefore restricted thiocolchicoside to short-term use only (max 7 days oral/IM), with contraindication in pregnancy, breastfeeding, and children under 16.
Drug Interactions
| Interacting Drug/Class | Effect | Clinical Action |
|---|---|---|
| CNS depressants (benzodiazepines, opioids, alcohol, antihistamines) | Enhanced sedation and CNS depression | Avoid combination; warn patient about alcohol |
| Other muscle relaxants (baclofen, tizanidine) | Additive muscle relaxation, respiratory depression risk | Avoid concurrent use |
| Anticoagulants (warfarin, heparin) | May potentiate bleeding risk | Monitor INR closely |
| Antiepileptics | Potential alteration in seizure threshold | Use with caution |
| Drugs metabolized by CYP450 | Possible pharmacokinetic interactions | Monitor for altered drug levels |
Contraindications
- Pregnancy and breastfeeding
- Women of childbearing age not using reliable contraception
- Children under 16 years
- Known hypersensitivity to colchicine or thiocolchicoside
- Chronic/long-term use (any indication)
- Severe hepatic impairment
2. ACECLOFENAC
Class: NSAID (preferential COX-2 inhibitor with some COX-1 activity; phenylacetic acid derivative - structurally related to diclofenac)
Usual Dose: 100 mg orally twice daily with food
Side Effects
Gastrointestinal (most common class effect):
- Nausea, vomiting, diarrhea, constipation
- Abdominal pain, dyspepsia, flatulence
- Peptic ulcer disease
- Gastrointestinal bleeding / perforation (less common than older NSAIDs due to preferential COX-2 activity)
Renal:
- Fluid retention, edema
- Acute kidney injury (especially with dehydration, elderly, or existing renal disease)
- Hyperkalemia
Cardiovascular:
- Elevated blood pressure
- Increased risk of MI and stroke (class effect of all NSAIDs, especially with prolonged use)
Hepatic:
- Raised liver enzymes (ALT, AST)
- Rare hepatotoxicity
Dermatological:
- Rash, pruritus
- Rare: Stevens-Johnson syndrome, toxic epidermal necrolysis (drug-induced Sweet syndrome also reported - Fitzpatrick's Dermatology)
- Photosensitivity
CNS:
- Headache, dizziness
- Visual disturbances
Hematological:
- Thrombocytopenia, anemia (rare)
Drug Interactions
As an NSAID, aceclofenac shares a broad and well-documented interaction profile. The Maudsley Prescribing Guidelines highlight NSAIDs (including aceclofenac) as causing clinically significant interactions with:
| Interacting Drug/Class | Mechanism & Effect | Clinical Action |
|---|---|---|
| Lithium | NSAIDs inhibit renal prostaglandins → reduced renal blood flow → increased lithium reabsorption. Lithium levels may rise 10-400%. Risk increased in renal impairment, heart failure, dehydration | Monitor lithium levels frequently; avoid if possible |
| Anticoagulants (warfarin) | Additive antiplatelet effect + GI mucosal damage → major bleeding risk | Avoid; if essential, monitor INR closely |
| Antihypertensives (ACE inhibitors, ARBs, diuretics, beta-blockers) | NSAIDs blunt their antihypertensive effect and increase risk of renal failure ("triple whammy" with ACEi + diuretic + NSAID) | Monitor BP and renal function |
| Diuretics (thiazide and loop) | Reduced diuretic efficacy; risk of acute renal failure especially in elderly or dehydrated patients | Use with caution; stay hydrated |
| Methotrexate | NSAIDs reduce renal excretion of methotrexate → toxicity risk (bone marrow suppression, mucositis) | Avoid combination; if unavoidable, use lowest NSAID dose and monitor |
| Corticosteroids | Significantly increased GI bleeding and ulceration risk | Avoid; if necessary, add a PPI |
| Other NSAIDs | Additive GI toxicity, no additional efficacy | Avoid combination |
| Digoxin | NSAIDs may increase digoxin levels (reduced renal clearance) | Monitor digoxin levels |
| Quinolone antibiotics (ciprofloxacin, etc.) | Additive CNS excitation → seizure risk | Use with caution |
| SSRIs / SNRIs | Additive antiplatelet effect → increased GI bleeding | Add PPI prophylaxis |
| Immunosuppressants (cyclosporine, tacrolimus) | Increased nephrotoxicity | Avoid; monitor renal function |
| Antidiabetics | NSAIDs may alter glucose control (sulfonylurea potentiation reported) | Monitor blood glucose |
Contraindications
- Active or history of peptic ulcer disease / GI bleeding
- Severe hepatic impairment (Child-Pugh C)
- Severe renal impairment (eGFR <30 ml/min)
- Active cardiovascular disease or high CV risk
- Pregnancy (especially third trimester - premature closure of ductus arteriosus)
- Breastfeeding
- Known hypersensitivity / aspirin-induced asthma triad (Samter's triad)
- Acute porphyria
3. COMBINATION: Aceclofenac + Thiocolchicoside
Indications: Musculoskeletal pain with muscle spasm - low back pain, torticollis, neck pain, sprains, strains, post-orthopedic surgery.
Additive Side Effects in Combination
- Drowsiness is significantly enhanced (both drugs have CNS effects)
- GI upset - use with food or a PPI is advised
- Dizziness - avoid driving or operating machinery
Special Population Cautions
| Population | Recommendation |
|---|---|
| Pregnancy | Contraindicated (both components) |
| Breastfeeding | Avoid |
| Children <16 years | Contraindicated |
| Elderly | High risk of GI bleeding and renal impairment; use lowest dose, shortest duration |
| Renal/hepatic impairment | Use with caution; dose adjustment or avoidance |
| Drivers | Warn about sedation and dizziness |
Key Safety Rules
- Limit thiocolchicoside to max 7 days (EMA/CHMP recommendation due to genotoxicity risk)
- Always prescribe with food to reduce GI side effects of aceclofenac
- Avoid in patients on warfarin, methotrexate, lithium without close monitoring
- Do not combine with alcohol - enhanced sedation and GI risk
- Female patients of childbearing age must use reliable contraception while on thiocolchicoside
Sources: EMA safety review on thiocolchicoside | Apollo Hospitals drug monograph | Truemeds clinical review | Maudsley Prescribing Guidelines, 15th ed. (NSAID-lithium interactions, p. 310) | Fitzpatrick's Dermatology (drug-induced Sweet syndrome)
This is a shared conversation. Sign in to Orris to start your own chat.